Cargando…

Risk stratification for upper tract urinary carcinoma

Upper tract urinary carcinoma (UTUC) is a heterogeneous group of rare tumors. The aim of this article is to critically review current therapeutic strategies and to propose a change in the risk-stratification of the disease. A non-systematic review of the literature was performed using the Medline da...

Descripción completa

Detalles Bibliográficos
Autores principales: Benamran, Daniel, Seisen, Thomas, Naoum, Elias, Vaessen, Christophe, Parra, Jérome, Mozer, Pierre, Shariat, Shahrokh F., Rouprêt, Morgan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475669/
https://www.ncbi.nlm.nih.gov/pubmed/32944543
http://dx.doi.org/10.21037/tau.2019.12.21
_version_ 1783579558011731968
author Benamran, Daniel
Seisen, Thomas
Naoum, Elias
Vaessen, Christophe
Parra, Jérome
Mozer, Pierre
Shariat, Shahrokh F.
Rouprêt, Morgan
author_facet Benamran, Daniel
Seisen, Thomas
Naoum, Elias
Vaessen, Christophe
Parra, Jérome
Mozer, Pierre
Shariat, Shahrokh F.
Rouprêt, Morgan
author_sort Benamran, Daniel
collection PubMed
description Upper tract urinary carcinoma (UTUC) is a heterogeneous group of rare tumors. The aim of this article is to critically review current therapeutic strategies and to propose a change in the risk-stratification of the disease. A non-systematic review of the literature was performed using the Medline database with the search terms: “upper tract urothelial carcinoma” together with “prognostic factor”, “risk stratification”, “risk factor”, “recurrence”, “predictive tool”, “nomograms” and “treatment”. Preoperative risk factors can be viewed as patient-related risk factors (gender, age, ethnicity, body mass index, smoking status, or genetic factors), or tumor-related risk factors (stage, grade, size, architecture, multifocality, ureteric obstruction). Several biomarkers, available either in blood, urine, or the tumor itself have also been proposed. However, many of these prognostic factors lack accuracy and validation in predicting oncological outcomes, despite their use in predictive tools. After risk stratification, kidney-sparing strategies should be considered (endoscopic management and segmental ureterectomy) and could benefit from new diagnostic tools and technical improvements in in situ adjuvant endocavitary instillations. Radical nephroureterectomy remains the first choice therapy for high-grade disease and will probably be associated with other treatments in the future (lymphadenectomy, perioperative chemotherapy, or immunotherapy). In view of the major recent improvements in UTUC treatment strategies, a new classification should be proposed, including low-, intermediate-, high- and very high-risk disease. Subgroup analysis of good quality trials and better understanding of UTUC risk factors will help validate this new approach toward more personalized medicine.
format Online
Article
Text
id pubmed-7475669
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-74756692020-09-16 Risk stratification for upper tract urinary carcinoma Benamran, Daniel Seisen, Thomas Naoum, Elias Vaessen, Christophe Parra, Jérome Mozer, Pierre Shariat, Shahrokh F. Rouprêt, Morgan Transl Androl Urol Review Article on Upper-Tract Urothelial Carcinoma: Current State and Future Directions Upper tract urinary carcinoma (UTUC) is a heterogeneous group of rare tumors. The aim of this article is to critically review current therapeutic strategies and to propose a change in the risk-stratification of the disease. A non-systematic review of the literature was performed using the Medline database with the search terms: “upper tract urothelial carcinoma” together with “prognostic factor”, “risk stratification”, “risk factor”, “recurrence”, “predictive tool”, “nomograms” and “treatment”. Preoperative risk factors can be viewed as patient-related risk factors (gender, age, ethnicity, body mass index, smoking status, or genetic factors), or tumor-related risk factors (stage, grade, size, architecture, multifocality, ureteric obstruction). Several biomarkers, available either in blood, urine, or the tumor itself have also been proposed. However, many of these prognostic factors lack accuracy and validation in predicting oncological outcomes, despite their use in predictive tools. After risk stratification, kidney-sparing strategies should be considered (endoscopic management and segmental ureterectomy) and could benefit from new diagnostic tools and technical improvements in in situ adjuvant endocavitary instillations. Radical nephroureterectomy remains the first choice therapy for high-grade disease and will probably be associated with other treatments in the future (lymphadenectomy, perioperative chemotherapy, or immunotherapy). In view of the major recent improvements in UTUC treatment strategies, a new classification should be proposed, including low-, intermediate-, high- and very high-risk disease. Subgroup analysis of good quality trials and better understanding of UTUC risk factors will help validate this new approach toward more personalized medicine. AME Publishing Company 2020-08 /pmc/articles/PMC7475669/ /pubmed/32944543 http://dx.doi.org/10.21037/tau.2019.12.21 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article on Upper-Tract Urothelial Carcinoma: Current State and Future Directions
Benamran, Daniel
Seisen, Thomas
Naoum, Elias
Vaessen, Christophe
Parra, Jérome
Mozer, Pierre
Shariat, Shahrokh F.
Rouprêt, Morgan
Risk stratification for upper tract urinary carcinoma
title Risk stratification for upper tract urinary carcinoma
title_full Risk stratification for upper tract urinary carcinoma
title_fullStr Risk stratification for upper tract urinary carcinoma
title_full_unstemmed Risk stratification for upper tract urinary carcinoma
title_short Risk stratification for upper tract urinary carcinoma
title_sort risk stratification for upper tract urinary carcinoma
topic Review Article on Upper-Tract Urothelial Carcinoma: Current State and Future Directions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475669/
https://www.ncbi.nlm.nih.gov/pubmed/32944543
http://dx.doi.org/10.21037/tau.2019.12.21
work_keys_str_mv AT benamrandaniel riskstratificationforuppertracturinarycarcinoma
AT seisenthomas riskstratificationforuppertracturinarycarcinoma
AT naoumelias riskstratificationforuppertracturinarycarcinoma
AT vaessenchristophe riskstratificationforuppertracturinarycarcinoma
AT parrajerome riskstratificationforuppertracturinarycarcinoma
AT mozerpierre riskstratificationforuppertracturinarycarcinoma
AT shariatshahrokhf riskstratificationforuppertracturinarycarcinoma
AT roupretmorgan riskstratificationforuppertracturinarycarcinoma